Patient-reported outcome (PRO) results from the AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum-resistant ovarian cancer (PROC)

被引：0

作者：

Hilbert, F. ^{[1
]}

Gropp-Meier, M. ^{[2
]}

Schmalfeldt, B. ^{[2
]}

Rau, J. ^{[3
]}

Meier, W. ^{[4
]}

Hasenburg, A. ^{[5
]}

Belau, A. ^{[6
]}

Vergote, I. ^{[7
]}

Zorr, A. ^{[8
]}

Hils, R. ^{[9
]}

Gerber, B. ^{[10
]}

du Bois, A. ^{[11
]}

Marme, F. ^{[12
]}

Mahner, S. ^{[13
]}

Canzler, U. ^{[14
]}

Lueck, H. -J. ^{[15
]}

Grischke, E. -M ^{[16
]}

Kurzeder, C. ^{[11
]}

机构：

[1] UKSH Campus Kiel, Klin Gynakol & Geburtshilfe, Kiel, Germany

[2] Gynakol Onkol & Brustzentrum, Oberschwabenklin, Ravensburg, Germany

[3] Univ Marburg, KKS, Marburg, Germany

[4] Evangel Krankenhaus, Frauenklin, Dusseldorf, Germany

[5] Univ Klin, Frauenklin, Freiburg, Germany

[6] Ernst Moritz Arndt Univ Greifswald, Univ Klinikum Greifswald, Klin & Poliklin Frauenheilkunde & Geburtshilfe, Greifswald, Germany

[7] Univ Hosp, Gynecol Oncol, Leuven, Belgium

[8] Klinikum Konstanz, Frauenklin, Constance, Germany

[9] HSK, Gynakol & Gynakol Onkol, Wiesbaden, Germany

[10] Klinikum Sudstadt, Univ Frauenklin & Poliklin, Rostock, Germany

[11] Kliniken Essen Mitte, Klin Gynakol Onkol, Essen, Germany

[12] Univ Frauenklin, Natl Ctr Tumorerkrankungen, Heidelberg, Germany

[13] Klinikum Univ Munchen, Klin & Poliklin Frauenheilkunde & Geburtshilfe, Munich, Germany

[14] Univ Klinikum Carl Gustav Carus, Klin & Poliklin Frauenheilkunde & Geburtshilfe, Dresden, Germany

[15] Gynakol Onkol Praxis Pelikanpl, Hannover, Germany

[16] Univ Klinikum Tubingen, Univ Frauenklin, Tubingen, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

0087

引用

页码：138 / 138

页数：1

共 46 条

[21] Primary results from ENGOT-Ov41/GEICO 69-O/ANITA, a double-blind placebo-controlled phase 3 trial evaluating atezolizumab combined with platinum-based chemotherapy and maintenance niraparib for recurrent ovarian cancer with a platinum-free interval >6 months
Gonzalez-Martin, Antonio
Rubio-Perez, Maria Jesus
Heitz, Florian
Christensen, Rene Depont
Colombo, Nicoletta
Gorp, Toon Van
Oaknin, Ana
Leary, Alexandra
Gaba, Lydia
Lebreton, Coriolan
Miguel De Sande Gonzalez, Luis
Romeo, Margarita
Redondo, Andres
Barretina-Ginesta, Maria-Pilar
Perez-Fidalgo, Alejandro
Santaballa, Ana
Bermejo, Maria Jose
Bruchim, Ilan
Ray-Coquard, Isabelle
Selle, Frederic
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A35 - A36
[22] ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled, phase 3 study of rucaparib plus nivolumab following front-line platinum-based chemotherapy in ovarian cancer
Goh, Jeffrey C.
Baron-Hay, Sally
Bonaventura, Tony
Buck, Martin
Dean, Andrew
Friedlander, Michael
Gao, Bo
Mileshkin, Linda
Oehler, Martin K.
Steer, Christopher
Vi Nguyen
Goble, Sandra
Grechko, Nikolay
Monk, Bradley J.
Kristeleit, Rebecca S.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 196 - 196
[23] ATHENA (GOG-3020/ENGOT-OV45): A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF RUCAPARIB plus NIVOLUMAB FOLLOWING FRONT-LINE PLATINUM-BASED CHEMOTHERAPY IN OVARIAN CANCER
Monk, B. J.
Coleman, R. L.
Fujiwara, K.
Oza, A. M.
Westin, S. N.
O'Malley, D. M.
Herzog, T. J.
Marme, F.
Oaknin, A.
Eskander, R.
Lorusso, D.
Korach, J.
Lin, K. K.
Shih, D.
Goble, S.
Grechko, N.
Hume, S.
Maloney, L.
McNeish, I.
Kristeleit, R. S.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 1019 - 1020
[24] PATIENT-REPORTED OUTCOMES FROM THE LUME-LUNG 1 TRIAL: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY IN SECOND-LINE ADVANCED NSCLC PATIENTS
Mellemgaard, Anders
Douillard, Jean-Yves
Novello, Silvia
Kaiser, Rolf
Orlov, Sergey
Krzakowski, Maciej
Von Pawel, Joachim
Gottfried, Maya
Bondarenko, Igor
Liao, Meilin
Barrueco, Jose
Gaschler-Markefski, Birgit
Griebsch, Ingolf
Reck, Martin
JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : S152 - S153
[25] ATHENA (GOG-3020/ENGOT-ov45): a randomized, double-blind, placebo-controlled, Phase III study of rucaparib plus nivolumab following front-line platinum-based chemotherapy in ovarian cancer
Westin, Shannon N.
Kristeleit, Rebecca S.
Coleman, Robert L.
Fujiwara, Keiichi
Oza, Amit M.
O'Malley, David M.
Herzog, Thomas J.
Marme, Frederik
Oaknin, Ana
Eskander, Ramez
Lorusso, Domenica
Safra, Tamar
Korach, Jacob
Lin, Kevin K.
Shih, Danny
Caunt, Lisa
Goble, Sandra
Hume, Stephanie
Maloney, Lara
McNeish, Iain
Monk, Bradley J.
CANCER RESEARCH, 2019, 79 (13)
[26] Patient-reported outcomes from a phase HI multicenter, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing alter chemotherapy: Cancer Oesophagus Gefitinib (COG)
Dutton, Susan J.
Blazeby, Jane M.
Petty, Russell D.
Mansoor, Wasat
Thompson, Joyce
Harrison, Mark
Abbas, Haider
Dahle-Smith, Asa
Chatterjee, Anirban
Falk, Stephen
Garcia-Alonso, Angel
Fyfe, David Walter
Hubner, Richard
Gamble, Tina
Peachey, Lynnda
Harvey, Christine
Julier, Patrick
Jankowski, Janusz
Midgley, Rachel
Ferry, David R.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
[27] Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial
Burris, Howard A., III
Okusaka, Takuji
Vogel, Arndt
Lee, Myung Ah
Takahashi, Hidenori
Breder, Valeriy
Blanc, Jean-Frederic
Li, Junhe
Bachini, Melinda
Zotkiewicz, Magdalena
Abraham, Jayne
Patel, Nikunj
Wang, Julie
Ali, Muzammil
Rokutanda, Nana
Cohen, Gordon
Oh, Do-Youn
LANCET ONCOLOGY, 2024, 25 (05): : 626 - 635
[28] Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer
Lorusso, Domenica
Hilpert, Felix
Gonzalez Martin, Antonio
Rau, Joern
Ottevanger, Petronella
Greimel, Elfriede
Lueck, Hans-Joachim
Selle, Frederic
Colombo, Nicoletta
Kroep, Judith R.
Mirza, Mansoor R.
Berger, Regina
Pardo, Beatriz
Grischke, Eva-Maria
Berton-Rigaud, Dominique
Martinez-Garcia, Jeronimo
Vergote, Ignace
Redondo, Andres
Cardona, Andres
Bastiere-Truchot, Lydie
du Bois, Andreas
Kurzeder, Christian
del Campo, J. M.
Bover, I.
Barretina-Ginesta, P.
Ortega, E.
Garcia, Y.
Romero, I.
Poveda, A.
Herrero, A.
Vidal, L.
Rubio, M. J.
Romeo, M.
Mendiola, C.
Arranz, J. A.
Santaballa, A.
Gomez de Liano, A.
Marme, F.
Mahner, S.
Canzler, U.
Zorr, A.
Gropp-Meier, M.
Cayir, P.
Schmalfeldt, B.
Rautenberg, B.
Meier, W.
Belau, A.
Gerber, B.
Rein, D.
Jackisch, C.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 (07) : 1141 - 1147
[29] Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Pujade-Lauraine, Eric
Ledermann, Jonathan A.
Selle, Frederic
Gebski, Val
Penson, Richard T.
Oza, Amit M.
Korach, Jacob
Huzarski, Tomasz
Poveda, Andres
Pignata, Sandro
Friedlander, Michael
Colombo, Nicoletta
Harter, Philipp
Fujiwara, Keiichi
Ray-Coquard, Isabelle
Banerjee, Susana
Liu, Joyce
Lowe, Elizabeth S.
Bloomfield, Ralph
Pautier, Patricia
LANCET ONCOLOGY, 2017, 18 (09): : 1274 - 1284
[30] Final safety results from ATHENA-MONO (GOG-3020/ENGOT-ov45), a randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer
O'Malley, David M.
Monk, Bradley J.
Lim, Myong Cheol
Pradera, Jose Fuentes
Buscema, Joseph
Wilson, Michelle K.
De Vivo, Rocco
Herzog, Thomas J.
Zagouri, Flora
Oza, Amit M.
Mikheeva, Olga N.
Diaz, John Paul
Lisyanskaya, Alla Sergeevna
Morris, Robert
Bruchim, Ilan
Craib, Marcia
Connor, Christy
Shih, Danny
Fujiwara, Keiichi
Kristeleit, Rebecca
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →